Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common diabetes pill treat anemia in MDS patients?

NCT ID NCT07516847

Disease control Sponsor: Seug yun Yoon, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether dapagliflozin, a drug used for diabetes, can help treat anemia in people with lower-risk myelodysplastic syndromes (MDS). Anemia is a common problem in MDS, causing fatigue and often requiring blood transfusions. The trial will give 37 participants dapagliflozin daily for 24 weeks to see if it raises hemoglobin levels and reduces transfusion needs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (a diabetes drug, also known as Forxiga)
What this could lead to
If it works, this could offer a new treatment option for anemia in lower-risk MDS patients, potentially reducing fatigue and the need for blood transfusions.
What could go wrong
This is a small, early-phase trial with only 37 participants and no placebo group. The drug may not improve anemia significantly, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 37 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years * Diagnosis of myelodysplastic syndromes (MDS) according to WHO or ICC criteria * Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk * Hemoglobin ≤10 g/dL at screening * Transfusion independent or low transfusion burden (Defined as ≤2 units of red blood cell transfusion within 8 weeks prior to enrollment) * If receiving erythropoiesis-stimulating agents (ESA) or other anemia-directed therapy, on a stable dose for at least 8 weeks prior to enrollment * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Absolute neutrophil count (ANC) ≥0.75 ×10⁹/L * Platelet count ≥50 ×10⁹/L * Adequate organ function: Creatinine clearance ≥30 mL/min AST or ALT ≤3 × upper limit of normal Exclusion Criteria: * IPSS-R intermediate-high or high-risk MDS * Transformation to acute myeloid leukemia or ≥20% blasts * Initiation or dose change of MDS- or anemia-directed therapy (e.g., ESA, luspatercept, hypomethylating agents) within 8 weeks prior to screening * Red blood cell transfusion \>2 units within 8 weeks prior to enrollment * Current use of SGLT2 inhibitors or history of serious adverse reaction to SGLT2 inhibitors * Uncontrolled diabetes mellitus (e.g., HbA1c \>10%) or history of diabetic ketoacidosis * Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m² * Active or uncontrolled infection * Absolute neutrophil count (ANC) \<0.75 ×10⁹/L or platelet count \<50 ×10⁹/L * Pregnant or breastfeeding women * Any condition that, in the investigator's judgment, would make participation inappropriate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Myelodysplastic syndromes (MDS)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.